Recombinant Human CD302/CLEC13A Fc Chimera Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

CD302, also known as CLEC13A and DCL1, is a type I transmembrane C-type lectin receptor.  It was identified while cloning human DEC-205 and was termed DCL1 (DEC-205-associated C-type lectin-1) (1). In humans, the highest expression of CD302 transcripts was observed in the liver, followed by lungs, spleen, and myeloid PBMC populations including monocytes, granulocytes, and dendritic cells (DC) (2). Human CD302 is synthesized as a 232 amino acid (aa) protein that includes 22 aa signal peptide, a 146 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 43 aa cytoplasmic region. The extracellular domain is predicted to contain eight beta strands and two ɑ helices using NMR (3).  Within the ECD, human CD302 shares 82% aa sequence identity with mouse and rat CD302. Unlike other classical C-type lectin receptors, CD302 is missing the known amino acid residues essential for calcium-dependent sugar binding, suggesting that CD302 may not have classic sugar binding capacity. However, CD302 did have the ability to behave as an endocytosis/phagocytosis receptor (1). In addition, CD302 was shown to colocalize with F-actin rich migratory structures, including filopodia, lamellipodia, and podosomes in macrophages, where CD302 may bind yet to be determined endothelial ligands involved in DC adhesion or migration (1, 2). Further evidence that CD302 is involved in regulating DC migration, includes that CD302 knockout mice had reduced frequency and numbers of migratory DC within the lymph nodes (LN) and reduced in vivo capacity to reach draining LN (2). CD302 was also found to exist as an intergenic splice variant able to form a fusion protein with DEC-205/CD205 in Hodgkin's lymphoma cell lines (4). The CD302/DEC-205 fusion protein was also found to be expressed by mature dendritic cells which altered endocytic capacity of DEC-205, although the wild-type single gene transcripts were the dominant isoforms expressed (5). Due to its selective expression in myeloid immune populations, CD302 has become a potential therapeutic target for acute myeloid leukemia (AML) (6).

Array 10203-CL

• CD302/CLEC13A Antibodies
• CD302/CLEC13A Lysate
• CD302/CLEC13A Proteins and Enzyme